Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Ophthalmic Inflammation and Infection
Published in: Journal of Ophthalmic Inflammation and Infection 1/2017

Open Access 01-12-2017 | Original research

Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS)—report 4: analysis and outcome of scleritis in an East Asian population

Authors: Muhammad Amir Bin Ismail, Rachel Hui Fen Lim, Helen Mi Fang, Elizabeth Poh Ying Wong, Ho Su Ling, Wee Kiak Lim, Stephen C. Teoh, Rupesh Agrawal

Published in: Journal of Ophthalmic Inflammation and Infection | Issue 1/2017

Login to get access

Abstract

Background

The purpose of this study is to evaluate the spectrum of scleritis from database of Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) at a tertiary eye referral eye institute in Singapore. Clinical records of 120 patients with scleritis from a database of 2200 patients from Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) were reviewed.

Results

56.6% were females, with a mean age of 48.6 ± 15.9 years. 75 (62.5%) had diffuse anterior scleritis, 25 (20.8%) had nodular anterior scleritis, 7 (5.8%) had necrotizing anterior scleritis and 13 (10.8%) had posterior scleritis. Ocular complications were observed in 53.3% of patients, including anterior uveitis (42.5%), raised intraocular pressure (12.5%), and corneal involvement (11.7%). Autoimmune causes were associated with 31 (25.8%) of patients, and 10 (8.3%) patients had an associated infective etiology, much higher than Caucasian studies. 53.3% of patients were treated with oral corticosteroids while 26.7% required immunosuppressives.

Conclusions

Infective etiology needs to be considered in patients of scleritis from Asian origin. In our study and in OASIS database, scleritis was associated with systemic autoimmune disease and ocular complications.
Literature
1.
McCluskey PJ, Wakefield D (1996) Scleritis and Episcleritis. In: Pepose JS, Holland GN, Wilhelms KR (eds) Ocular inflammation and immunity. Mosby, St Louis, pp 642–647
2.
3.
4.
Sainz de la Maza M, Jabbur NS, Foster CS (1994) Severity of scleritis and episcleritis. Ophthalmology 101:389–396CrossRefPubMed
5.
Albini TA, Rao NA, Smith RE (2005) The diagnosis and management of anterior scleritis. Int Ophthalmol Clin 45:191–204CrossRefPubMed
6.
Smith JR, Mackensen F, Rosenbaum JT (2007) Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol 3:219–226CrossRefPubMed
7.
Pavesio CE, Meier FM (2001) Systemic disorders associated with episcleritis and scleritis. Curr Opin Ophthalmol 12:471–478CrossRefPubMed
8.
Jabs DA, Mudun A, Dunn JP et al (2000) Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol 130:469–476CrossRefPubMed
9.
10.
Lin P, Bhullar SS, Tessler HH et al (2008) Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis. Am J Ophthalmol 145:463–471CrossRefPubMed
11.
12.
Shah SS, Lowder CY, Schmitt MA et al (1992) Low dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 99:1419–1423CrossRefPubMed
13.
Throne EJ, Jabs DA, Qaiz FA et al (2005) Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112:1472–1477CrossRef
14.
Murphy CC, Ayliffe WH, Booth A et al (2004) Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111:352–356CrossRefPubMed
15.
Chauhan S, Kamal A, Thompson RN et al (2009) Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol 93:984–985CrossRefPubMed
16.
Doctor P, Sultan A, Syed S et al (2010) Infliximab for the treatment of refractory scleritis. Br J Ophthalmol 94:579–583CrossRefPubMed
17.
Iaccheri B, Androudi S, Bocci EB et al (2010) Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm 18:223–225CrossRefPubMed
18.
Kurz PA, Suhler EB, Choi D, Rosenbaum JT (2009) Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol 93:546–548CrossRefPubMed
19.
Restrepo JP, Molina MP (2010) Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol 29:559–561CrossRefPubMed
20.
21.
Suhler EB, Lim LL, Beardsley RM et al (2014) Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology 121(10):1885–1891CrossRefPubMed
22.
Nakajima N, Hayasaka S (1995) Clinical features of episcleritis and scleritis in some Japanese patients. Ophthalmologica 209:256e9CrossRef
23.
Anshu A, Chee SP (2007) Posterior scleritis and its association with HLA B27 haplotype. Ophthalmologica 221:275e8CrossRef
24.
Keino H, Watanabe T, Taki W et al (2010) Clinical features and visual outcomes of Japanese patients with scleritis. Br J Ophthalmol 94:1459–1463CrossRefPubMed
25.
Sainz de la Maza M, Foster CS, Jabbur NS (1995) Scleritis associated with systemic vasculitic diseases. Ophthalmology 102:687–692CrossRefPubMed
26.
McGavin DDM, Williamson J, Forrester JV et al (1976) Episcleritis and scleritis. A study of their clinical manifestation and association with rheumatoid arthritis. Br J Ophthalmol 60:192e226CrossRef
27.
Araki K, Nakagawa Y, Tada R et al (1987) Clinical features of 75 cases of scleritis during the past 11 years. Jpn J Clin Ophthalmol 41:1075e8
28.
Kurosaka H, Muraki Y, Suzuki S (1994) Evaluation of 106 cases of scleritis in our hospital. Folia Ophthalmol Jpn 45:797e803
29.
Zhou Y, Wang Z, Zhang Y et al (2014) Study on the clinical manifestation of 90 cases with scleritis and episcleritis. Zhonghua Yan Ke Za Zhi 50(4):261–266PubMed
30.
Berchicci L, Miserocchi E, Di Nicola M et al (2014) Clinical features of patients with episcleritis and scleritis in an Italian tertiary care referral center. Eur J Ophthalmol 24(3):293–298CrossRefPubMed
31.
Wieringa WG, Wieringa JE, ten Dam-van Loon NH et al (2013) Visual outcome, treatment results, and prognostic factors in patients with scleritis. Ophthalmology 120(2):379–386CrossRefPubMed
32.
33.
34.
McCluskey PJ, Watson PG, Lightman S, Scleritis P et al (1999) Clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology 106:2380–2386CrossRefPubMed
35.
Kim EC, Foster CS (2006) Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. Int Ophthalmol Clin 46:141–164CrossRefPubMed
36.
Sainz de la Maza M, Jabbur NS, Foster CS (1993) An analysis of therapeutic decision for scleritis. Ophthalmology 100:1372–1376CrossRefPubMed
37.
Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–516CrossRefPubMed
Metadata
Title
Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS)—report 4: analysis and outcome of scleritis in an East Asian population
Authors
Muhammad Amir Bin Ismail
Rachel Hui Fen Lim
Helen Mi Fang
Elizabeth Poh Ying Wong
Ho Su Ling
Wee Kiak Lim
Stephen C. Teoh
Rupesh Agrawal
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Journal of Ophthalmic Inflammation and Infection / Issue 1/2017
Electronic ISSN: 1869-5760
DOI
https://doi.org/10.1186/s12348-017-0124-5

Other articles of this Issue 1/2017

Journal of Ophthalmic Inflammation and Infection 1/2017 Go to the issue

Original research

A retrospective cohort study of patients treated with anti-tuberculous therapy for presumed ocular tuberculosis

Original research

Distinguishing features of acute Vogt-Koyanagi-Harada disease and acute central serous chorioretinopathy on optical coherence tomography angiography and en face optical coherence tomography imaging

Brief report

Optic disc granuloma with epididymitis: a diagnostic challenge

Brief report

Wide-field fluorescein and indocyanine green angiography findings in the eyes with Vogt-Koyanagi-Harada disease

Original research

Tuberculous uveitis: association between anti-tuberculous therapy and clinical response in a non-endemic country

Brief report

Anterior segment optical coherence tomography and retained vegetal intraocular foreign body masquerading as chronic anterior uveitis